Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Dividend Discount Model (DDM)
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Solvency ratios for the analyzed period demonstrate a generally stable, though fluctuating, financial position. Several metrics indicate a moderate level of financial leverage, with some notable shifts in interest and fixed charge coverage over the five-year span.
- Debt Levels Relative to Equity and Capital
- The Debt to Equity ratio decreased from 1.27 in 2021 to 1.09 in 2023, suggesting a reduction in reliance on debt financing relative to equity. However, this trend reversed in 2024, with the ratio increasing to 1.38 before decreasing slightly to 1.10 in 2025. A similar pattern is observed when including operating lease liabilities. The Debt to Capital ratio exhibits a more consistent, albeit slight, decline from 0.56 in 2021 to 0.52 in 2023, followed by an increase to 0.58 in 2024 and a return to 0.52 in 2025. These ratios indicate that the proportion of debt financing within the company’s capital structure remained relatively stable overall, with a temporary increase in 2024.
- Debt as a Percentage of Assets
- The Debt to Assets ratio experienced a gradual increase from 0.39 in 2021 to 0.45 in 2024, indicating a growing proportion of assets financed by debt. This was partially offset by a decrease to 0.42 in 2025. Inclusion of operating lease liabilities shows a similar trend, moving from 0.40 to 0.46 and then back to 0.43. This suggests a moderate increase in the company’s asset financing through debt, with a slight moderation in the most recent year.
- Leverage and Coverage Ratios
- Financial leverage, as measured by the ratio, decreased steadily from 3.23 in 2021 to 2.72 in 2023, indicating a reduced use of debt to amplify returns. It then increased to 3.05 in 2024 before decreasing to 2.60 in 2025. The Interest Coverage ratio declined significantly from 9.27 in 2021 to 7.22 in 2022, then recovered to 8.27 in 2023, before a substantial drop to 1.71 in 2024. A strong recovery to 10.57 is observed in 2025. The Fixed Charge Coverage ratio mirrors this pattern, decreasing from 8.15 to 6.30, recovering to 7.18, then falling to 1.61 in 2024, and finally rebounding to 9.21 in 2025. The dramatic decline in coverage ratios in 2024, followed by a strong recovery in 2025, warrants further investigation to understand the underlying drivers of this volatility.
In summary, the company maintained a moderate level of debt financing throughout the period. While debt levels relative to equity and assets fluctuated, the most significant changes were observed in the coverage ratios, particularly in 2024 and 2025, suggesting a potential shift in earnings or interest expense that requires further scrutiny.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Total Gilead stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The Debt-to-Equity ratio for the analyzed period demonstrates fluctuations, indicating shifts in the company’s financial leverage. Initially, the ratio decreased before increasing and then decreasing again, suggesting dynamic changes in the capital structure.
- Overall Trend
- The Debt-to-Equity ratio began at 1.27 in 2021, decreased to 1.19 in 2022, and further decreased to 1.09 in 2023. A notable increase occurred in 2024, reaching 1.38, before declining to 1.10 in 2025. This pattern suggests periods of decreasing reliance on debt financing followed by increased borrowing and subsequent reduction.
- Year-over-Year Changes
- From 2021 to 2022, the ratio decreased by 0.08, indicating a reduction in financial leverage. The decrease continued from 2022 to 2023, with a change of -0.10, further suggesting a strengthening equity position relative to debt. However, 2024 saw a significant increase of 0.29, representing a substantial rise in debt relative to equity. The final period, 2024 to 2025, showed a decrease of 0.28, partially offsetting the prior year’s increase.
- Debt and Equity Movements
- Total debt decreased from US$26,695 million in 2021 to US$24,987 million in 2023, contributing to the initial decline in the ratio. It then increased to US$26,711 million in 2024 before decreasing again to US$24,936 million in 2025. Total stockholders’ equity generally increased from US$21,069 million in 2021 to US$22,833 million in 2023, supporting the lower Debt-to-Equity ratio during those years. A decrease in equity to US$19,330 million in 2024 contributed to the ratio’s increase, followed by a recovery to US$22,703 million in 2025.
The observed fluctuations in the Debt-to-Equity ratio warrant further investigation to understand the underlying strategic decisions and financial circumstances driving these changes. The increase in 2024, followed by a decrease in 2025, suggests potential short-term financing activities or shifts in investment strategies.
Debt to Equity (including Operating Lease Liability)
Gilead Sciences Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liabilities, current (classified as Other accrued liabilities) | ||||||
| Operating lease liabilities, noncurrent (classified as Other long-term obligations) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Gilead stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The Debt to Equity ratio, including operating lease liability, exhibited fluctuations over the five-year period. Total debt, inclusive of operating leases, generally remained relatively stable, while stockholders’ equity experienced more pronounced changes, influencing the overall ratio.
- Overall Trend
- The Debt to Equity ratio decreased from 1.30 in 2021 to 1.12 in 2022, indicating a strengthening of the equity position relative to debt. However, the ratio increased significantly to 1.41 in 2023, suggesting increased leverage. A subsequent decrease to 1.13 in 2024 was observed, followed by a further decrease to 1.13 in 2025.
- Debt Evolution
- Total debt decreased from US$27,285 million in 2021 to US$25,808 million in 2022, and further to US$25,658 million in 2023. An increase to US$27,322 million occurred in 2024, before decreasing again to US$25,541 million in 2025. These changes suggest active debt management, though with a notable increase in 2024.
- Equity Evolution
- Total stockholders’ equity increased from US$21,069 million in 2021 to US$21,240 million in 2022, and continued to rise to US$22,833 million in 2023. A substantial decrease to US$19,330 million was recorded in 2024, before recovering to US$22,703 million in 2025. The 2024 decrease significantly impacted the Debt to Equity ratio.
The interplay between debt and equity levels demonstrates a dynamic financial structure. The increase in the Debt to Equity ratio in 2023, despite a relatively stable debt position, was primarily driven by the growth in equity. Conversely, the increase in 2024 was driven by an increase in debt and a decrease in equity. The return to lower levels in 2025 suggests a rebalancing of the capital structure.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Total Gilead stockholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio for the analyzed period demonstrates a generally stable trend with some fluctuation. Initial values indicate a moderate level of debt financing relative to total capital. Over the five-year period, the ratio exhibits a slight overall decrease followed by a recent increase.
- Debt to Capital Ratio - Trend Analysis
- The Debt to Capital ratio decreased from 0.56 in 2021 to 0.52 in 2023, suggesting a reduction in the proportion of debt used to finance the company’s assets relative to equity and other capital sources. This decrease indicates a strengthening of the capital structure from a leverage perspective. However, in 2024, the ratio increased to 0.58, representing the highest value in the observed period. The most recent year, 2025, shows a slight decrease back to 0.52, mirroring the 2023 level.
- Debt to Capital Ratio - Magnitude
- Throughout the period, the ratio remained within a relatively narrow range, fluctuating between 0.52 and 0.58. These values suggest a moderate reliance on debt financing. A ratio consistently above 0.5 indicates that more than half of the company’s capital is financed through debt, which carries associated financial risks.
- Debt and Capital Amounts
- Total debt decreased from US$26,695 million in 2021 to US$24,936 million in 2025, with a temporary increase to US$26,711 million in 2024. Total capital also experienced a decrease from US$47,764 million in 2021 to US$47,639 million in 2025, with a similar temporary decrease in 2024 to US$46,041 million. The interplay between these changes in absolute values contributes to the observed fluctuations in the Debt to Capital ratio.
The increase in the Debt to Capital ratio in 2024 warrants further investigation to understand the underlying reasons, such as increased borrowing or a decrease in equity. The return to 0.52 in 2025 suggests a potential correction or stabilization of the capital structure.
Debt to Capital (including Operating Lease Liability)
Gilead Sciences Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liabilities, current (classified as Other accrued liabilities) | ||||||
| Operating lease liabilities, noncurrent (classified as Other long-term obligations) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Gilead stockholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio, inclusive of operating lease liabilities, demonstrates a relatively stable pattern over the five-year period. While fluctuations are present, the ratio remains within a constrained range, indicating a consistent, though not dramatically changing, capital structure.
- Overall Trend
- The ratio exhibits a slight decreasing trend from 2021 to 2023, followed by an increase in 2024, and a subsequent decrease in 2025. This suggests periods of both increased and decreased reliance on debt financing relative to the overall capital base.
- Detailed Ratio Analysis
- In 2021, the Debt to Capital ratio stood at 0.56. It decreased to 0.55 in 2022 and further to 0.53 in 2023, representing a modest reduction in leverage. A notable increase occurred in 2024, with the ratio rising to 0.59, indicating a higher proportion of debt in the capital structure. The ratio then decreased again in 2025, settling at 0.53, mirroring the 2023 level.
- Component Analysis
- Total debt, including operating lease liability, decreased from US$27,285 million in 2021 to US$25,808 million in 2022, and US$25,658 million in 2023. It then increased to US$27,322 million in 2024 before decreasing to US$25,541 million in 2025. Total capital, inclusive of operating lease liability, followed a similar pattern, decreasing from US$48,354 million in 2021 to US$47,048 million in 2022, increasing to US$48,491 million in 2023, decreasing to US$46,652 million in 2024, and increasing to US$48,244 million in 2025. The interplay between these two components drives the observed fluctuations in the Debt to Capital ratio.
The observed fluctuations suggest active capital management, potentially influenced by financing activities, acquisitions, or changes in operational needs. The ratio’s return to 0.53 in 2025 indicates a stabilization after the 2024 increase.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt-to-Assets ratio exhibits a generally stable pattern with a slight increasing trend over the observed period. Initial values indicate a ratio of 0.39 in 2021, increasing to 0.40 in both 2022 and 2023. A more noticeable increase is observed in 2024, reaching 0.45, before decreasing slightly to 0.42 in 2025.
- Total Debt
- Total debt decreased from US$26,695 million in 2021 to US$25,230 million in 2022, and further to US$24,987 million in 2023. An increase to US$26,711 million is noted in 2024, followed by a decrease to US$24,936 million in 2025. These fluctuations in total debt contribute to the observed changes in the Debt-to-Assets ratio.
- Total Assets
- Total assets experienced a decline from US$67,952 million in 2021 to US$63,171 million in 2022, and continued to decrease to US$62,125 million in 2023. A further reduction to US$58,995 million occurred in 2024, with a slight recovery to US$59,023 million in 2025. The consistent decrease in total assets, particularly between 2021 and 2024, plays a significant role in the increasing Debt-to-Assets ratio.
The combined effect of fluctuating debt levels and decreasing asset values resulted in the observed trend. The increase in the ratio from 0.39 in 2021 to 0.45 in 2024 suggests a growing reliance on debt financing relative to the company’s asset base. The slight decrease in 2025 indicates a potential stabilization, but the ratio remains higher than the initial value recorded in 2021.
- Ratio Interpretation
- A Debt-to-Assets ratio of 0.40 to 0.45 generally indicates a moderate level of financial leverage. While not excessively high, the increase observed in recent years warrants monitoring to assess potential risks associated with increased debt burden relative to asset holdings.
Debt to Assets (including Operating Lease Liability)
Gilead Sciences Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt, net | ||||||
| Long-term debt, net, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liabilities, current (classified as Other accrued liabilities) | ||||||
| Operating lease liabilities, noncurrent (classified as Other long-term obligations) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio, including operating lease liability, exhibits a generally stable pattern with a slight increasing trend over the observed period. Total debt remained relatively consistent between 2021 and 2023, before increasing in 2024 and decreasing slightly in 2025. Simultaneously, Total Assets experienced a decline from 2021 to 2024, followed by a modest increase in 2025.
- Debt to Assets Ratio Trend
- The ratio began at 0.40 in 2021, increasing to 0.41 in both 2022 and 2023. A more noticeable increase occurred in 2024, reaching 0.46, before decreasing slightly to 0.43 in 2025. This suggests a growing reliance on debt financing relative to assets, particularly in 2024, although this trend partially reversed in the following year.
- Total Debt Analysis
- Total debt decreased from $27,285 million in 2021 to $25,808 million in 2022, and further to $25,658 million in 2023. An increase to $27,322 million was observed in 2024, followed by a decrease to $25,541 million in 2025. These fluctuations indicate active debt management, potentially through repayments, issuances, or changes in operating lease obligations.
- Total Assets Analysis
- Total assets decreased consistently from $67,952 million in 2021 to $58,995 million in 2024. A slight recovery was seen in 2025, with assets reaching $59,023 million. This decline in asset value, concurrent with the increase in debt in 2024, contributed to the peak in the Debt to Assets ratio during that year.
The interplay between debt and asset values suggests a dynamic financial position. While the company maintains a moderate level of debt relative to its assets, the increase in the ratio in 2024 warrants attention, particularly in the context of declining asset values. The slight improvement in 2025 offers a partial offset to this concern.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Total Gilead stockholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An examination of the financial information reveals trends in the company’s financial leverage over a five-year period. Total assets decreased from 2021 to 2024, before stabilizing in 2025. Stockholders’ equity exhibited some fluctuation, increasing in 2022 and 2023, decreasing significantly in 2024, and then recovering in 2025. These movements in the balance sheet components are reflected in the financial leverage ratio.
- Financial Leverage
- The financial leverage ratio decreased from 3.23 in 2021 to 2.72 in 2023, indicating a reduction in the proportion of assets financed by equity. This suggests a lessening reliance on financial leverage during this period. However, the ratio increased to 3.05 in 2024, reversing the prior trend, before decreasing again to 2.60 in 2025. The increase in 2024 coincides with the substantial decrease in stockholders’ equity, suggesting that the company utilized more debt financing relative to equity during that year. The subsequent decrease in 2025, alongside the recovery in stockholders’ equity, indicates a return towards a lower level of financial leverage.
Overall, the company’s financial leverage has demonstrated some volatility. While a general downward trend was evident from 2021 to 2023, the ratio increased in 2024 before declining again in 2025. The fluctuations in financial leverage appear to be correlated with changes in stockholders’ equity, suggesting that equity financing plays a significant role in the company’s capital structure.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio exhibited considerable fluctuation over the five-year period. Initial values were strong, followed by a significant decline, and then a recovery towards the end of the analyzed timeframe.
- Earnings Before Interest and Tax (EBIT)
- EBIT demonstrated a decrease from US$9,279 million in 2021 to US$6,749 million in 2022. A partial recovery was observed in 2023, reaching US$7,803 million, but this was followed by a substantial drop to US$1,667 million in 2024. A strong rebound occurred in 2025, with EBIT increasing to US$10,820 million.
- Interest Expense
- Interest expense remained relatively stable between 2021 and 2023, fluctuating between US$935 million and US$1,001 million. A slight increase was noted in 2024, reaching US$977 million, and continued into 2025 with a value of US$1,024 million. The changes in interest expense were less pronounced than those observed in EBIT.
- Interest Coverage Ratio
- The interest coverage ratio began at 9.27 in 2021, indicating a strong ability to meet interest obligations. It decreased to 7.22 in 2022, and further to 8.27 in 2023. A dramatic decline was evident in 2024, with the ratio falling to 1.71, suggesting a significantly reduced capacity to cover interest expenses. The ratio experienced a substantial recovery in 2025, rising to 10.57, surpassing the initial value from 2021 and indicating a restored, and even improved, ability to cover interest obligations.
The significant drop in the interest coverage ratio in 2024 warrants attention, coinciding with the lowest EBIT value during the period. However, the subsequent recovery in 2025, driven by a substantial increase in EBIT, suggests this was a temporary downturn. The overall trend highlights a sensitivity of the interest coverage ratio to fluctuations in earnings.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | ||||||
| Add: Net income attributable to noncontrolling interest | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease cost, including variable lease and short-term lease cost | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense | ||||||
| Operating lease cost, including variable lease and short-term lease cost | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company’s fixed charge coverage exhibited considerable fluctuation between 2021 and 2025. Initial coverage was strong, declining significantly in 2022, followed by a partial recovery, a substantial drop in 2024, and a strong rebound in 2025.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax decreased from US$9,435 million in 2021 to US$6,911 million in 2022, representing a decline of approximately 26.7%. A subsequent increase to US$7,968 million was observed in 2023, but this was followed by a dramatic reduction to US$1,830 million in 2024. Earnings then experienced a significant recovery, reaching US$10,989 million in 2025, exceeding the 2021 level.
- Fixed Charges
- Fixed charges remained relatively stable between 2021 and 2023, fluctuating between US$1,097 million and US$1,157 million. A slight increase to US$1,140 million was noted in 2024, followed by a further increase to US$1,193 million in 2025. The overall trend indicates a modest, consistent rise in fixed charge obligations over the five-year period.
- Fixed Charge Coverage
- The fixed charge coverage ratio began at 8.15 in 2021, indicating a strong ability to meet fixed obligations. This ratio decreased to 6.30 in 2022, signaling a reduced margin of safety. A partial recovery to 7.18 occurred in 2023, but the ratio plummeted to 1.61 in 2024, suggesting a limited capacity to cover fixed charges. The ratio rebounded sharply to 9.21 in 2025, surpassing the initial 2021 level and indicating a restored, and even improved, ability to meet fixed obligations.
The volatility in fixed charge coverage appears to be primarily driven by fluctuations in earnings before fixed charges and tax, with fixed charges remaining comparatively consistent. The substantial decline in 2024 and subsequent recovery in 2025 warrant further investigation to understand the underlying operational and financial factors contributing to these shifts.